Drugs / PV-001-DC
PV-001-DC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03990493 | Apr → Sep 2024 | melanoma | PrimeVax Immuno-Oncology Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03803397 | Apr → Aug 2024 | metastatic melanoma | PrimeVax Immuno-Oncology Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PV-001-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03803397 ↗ |
| Known as | Autologous Monocyte-derived Lysate Pulsed Dendritic Cells | “Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)” NCT03990493 ↗ |
| Modality | Cell therapy | “Autologous monocyte-derived dendritic cells pulsed with tumor lysate (PV-001-DC)” NCT03803397 ↗ |
| Route | Intravenous | “The PV-001-DC product will be infused into the patient's vein.” NCT03803397 ↗ |